-

Fractyl Health Mourns the Passing of Esteemed Board Member Brian Dovey

LEXINGTON, Mass.--(BUSINESS WIRE)--It is with profound sadness that Fractyl Health announces the passing of Brian Dovey, a cherished member of our Board of Directors and a partner at Domain Associates, following a short illness.

With a career spanning more than four decades in the life sciences sector, Brian was a stalwart in the industry, contributing immeasurably to its growth and evolution. His extensive expertise, leadership, and insight were instrumental in guiding numerous companies, including Fractyl Health, towards innovative solutions offering new options for patients.

"Brian's passing is a deep loss for me, the Fractyl Health family and the broader life sciences venture capital community," said Dr. Harith Rajagopalan, Co-founder and CEO of Fractyl Health. "He was not only a visionary leader but also a mentor and a friend. His legacy will continue to inspire and guide our efforts.”

Over the years, Brian's leadership roles spanned various organizations, from venture capital firms to biopharmaceutical companies, leaving an indelible mark wherever he went. His passion for fostering innovative medical solutions has led to breakthroughs that continue to benefit patients worldwide.

The entire Fractyl Health team extends its heartfelt condolences to Brian's family, friends, and colleagues. We will forever remember and honor his commitment to advancing healthcare, his pithy quips, and his unwavering support for our mission.

About Fractyl Health

Fractyl Health is focused on pioneering new approaches to the treatment of T2D. Despite advances in treatment over the last 50 years, T2D and obesity continue to be rapidly growing drivers of morbidity and mortality in the 21st century. Fractyl Health’s goal is to transform T2D treatment from chronic blood glucose management to disease-modifying therapies that target the organ-level root causes of the disease. Fractyl Health is a private organ-editing metabolic therapeutics company based in Lexington, MA. For more information, visit www.fractyl.com or www.twitter.com/FractylHealth.

Contacts

Corporate Contact
Lisa Davidson, Chief Financial Officer
Lisa@fractyl.com, 781.902.8800

Media Contact
Beth Brett, Corporate Communications
Bbrett@fractyl.com, 720.656.6544

Fractyl Health


Release Versions

Contacts

Corporate Contact
Lisa Davidson, Chief Financial Officer
Lisa@fractyl.com, 781.902.8800

Media Contact
Beth Brett, Corporate Communications
Bbrett@fractyl.com, 720.656.6544

Social Media Profiles
More News From Fractyl Health

Fractyl Health Demonstrated Significant Improvement in Weight Loss in Head-to-Head Preclinical Obesity Studies of its Rejuva® GLP-1-Based Pancreatic Gene Therapy Candidate (GLP-1 PGTx) Compared to Chronic Semaglutide at EASD’s Annual Meeting

LEXINGTON, Mass.--(BUSINESS WIRE)--Fractyl Health, a metabolic therapeutics company focused on pioneering new approaches for the treatment of type 2 diabetes (T2D) and obesity, presented preclinical findings from its Rejuva® gene therapy platform at the European Association for the Study of Diabetes (EASD) 2023 Annual Meeting. The oral presentation, titled “Pancreatic Gene Therapy Durably Improves Glycemia and Delays Disease Progression in a Murine Model of Type 2 Diabetes,” highlighted the pro...

Fractyl Health to Present Pioneering Data on Revita® and Rejuva® Programs at the European Association for the Study of Diabetes (EASD) 2023 Scientific Congress

LEXINGTON, Mass.--(BUSINESS WIRE)--Fractyl Health, a metabolic therapeutics company focused on pioneering new approaches to the treatment of metabolic diseases, including type 2 diabetes (T2D) and obesity, announced today its upcoming abstract presentations at the European Association for the Study of Diabetes (EASD) 2023 Scientific Congress. The congress will be held virtually and in person in Hamburg, Germany, from October 2-6, 2023. Fractyl Health is set to present noteworthy updates on its...

Fractyl Health Welcomes Dr. Timothy Kieffer as Chief Scientific Officer

LEXINGTON, Mass.--(BUSINESS WIRE)--Fractyl Health, a metabolic therapeutics company focused on pioneering new approaches to the treatment of metabolic diseases, including type 2 diabetes (T2D) and obesity, proudly announces the appointment of Dr. Timothy Kieffer as its Chief Scientific Officer. Dr. Kieffer's unparalleled expertise in gut and pancreas biology and the development of gene and cell therapies for diabetes will further bolster Fractyl Health's vision of reshaping diabetes care and me...
Back to Newsroom